Literature DB >> 21167836

Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratope.

David C Lowe1, Stefan Gerhardt, Alison Ward, David Hargreaves, Malcolm Anderson, Franco Ferraro, Richard A Pauptit, Debbie V Pattison, Catriona Buchanan, Bojana Popovic, Donna K Finch, Trevor Wilkinson, Matthew Sleeman, Tristan J Vaughan, Philip R Mallinder.   

Abstract

Interleukin (IL) 15 is an inflammatory cytokine that plays an essential role in the activation, proliferation, and maintenance of specific natural killer cell and T-cell populations, and has been implicated as a mediator of inflammatory diseases. An anti-IL-15 antibody that blocked IL-15-dependent cellular responses was isolated by phage display and optimised via mutagenesis of the third complementarity-determining regions (CDRs) of variable heavy (VH) and variable light chains. Entire repertoires of improved variants were recombined with each other to explore the maximum potential sequence space. DISC0280, the most potent antibody isolated using this comprehensive strategy, exhibits a 228-fold increase in affinity and a striking 40,000-fold increase in cellular potency compared to its parent. Such a wholesale recombination strategy therefore represents a useful method for exploiting synergistic potency gains as part of future antibody engineering efforts. The crystal structure of DISC0280 Fab (fragment antigen binding), in complex with human IL-15, was determined in order to map the structural epitope and paratope. The most remarkable feature revealed lies within the paratope and is a novel six-amino-acid α-helix that sits within the VH CDR3 loop at the center of the antigen binding site. This is the first report to describe an α-helix as a principal component of a naturally derived VH CDR3 following affinity maturation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167836     DOI: 10.1016/j.jmb.2010.12.017

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  4 in total

1.  The VH framework region 1 as a target of efficient mutagenesis for generating a variety of affinity-matured scFv mutants.

Authors:  Yuki Kiguchi; Hiroyuki Oyama; Izumi Morita; Yasuhiro Nagata; Naoko Umezawa; Norihiro Kobayashi
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

2.  Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.

Authors:  Gen-Shen Zhong; Min-Na Wu; Xiao-Fang Guo; Zhi-Shan Xu; Sheng-Hua Zhang; Yong-Su Zhen
Journal:  Oncol Lett       Date:  2013-01-18       Impact factor: 2.967

3.  Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα.

Authors:  W Mark Abbott; Melanie Snow; Sonia Eckersley; Jonathan Renshaw; Gareth Davies; Richard A Norman; Peter Ceuppens; Jerry Slootstra; Joris J Benschop; Yoshitomo Hamuro; Jessica E Lee; Peter Newham
Journal:  Biosci Rep       Date:  2013-08-23       Impact factor: 3.840

4.  Tailored amino acid diversity for the evolution of antibody affinity.

Authors:  Andrea González-Muñoz; Evert Bokma; Desmond O'Shea; Kevin Minton; Martin Strain; Katherine Vousden; Christine Rossant; Lutz Jermutus; Ralph Minter
Journal:  MAbs       Date:  2012-08-27       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.